Safety and Immunogenicity of a Candidate CHIKV Vaccine (CHIK001)

Summary

A phase I dose escalation study to assess the safety and immunogenicity of the candidate vaccine ChAdOx1 Chik in healthy volunteers. Volunteers will be recruited and vaccinated in Oxford, England. All vaccinations will be administered intramuscularly. Three different doses will be tested (5x10\^9 vp, 2.5x10\^10 vp and 5x10\^10vp). The total duration of the study will be 26 weeks from the day of enrolment for all volunteers.

Timeline

Start

2018-07-31

Primary completion

2019-09-30

Completion

2019-09-30

Outcome

Met primary endpoint

paper ChAdOx1 Chik was safe at all doses tested with no serious adverse reactions reported. PMID 34330906 ↗

Publications

• Folegatti PM, Harrison K, Preciado-Llanes L, Lopez FR, Bittaye M, Kim YC, Flaxman A, Bellamy D, Makinson R, Sheridan J, Azar SR, Campos RK, Tilley M, Tran N, Jenkin D, Poulton I, Lawrie A, Roberts R, Berrie E, Rossi SL, Hill A, Ewer KJ, Reyes-Sandoval A. A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial. Nat Commun. 2021 Jul 30;12(1):4636. doi: 10.1038/s41467-021-24906-y.

Drugs

Indications